National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Ivacaftor (Kalydeco®) for the treatment of CF patients with the R117H mutation.

Kalydeco® for the treatment of patients with cystic fibrosis aged 18 years and older who have the R117H mutation in the CFTR gene.

Rapid Review

Commenced Completed Outcome
14/01/2016 10/02/2016 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
15/04/2016  05/01/2017 Reimbursement Not Recommended at the Submitted Price


The HSE has approved reimbursement following confidential price negotiations.